H
Honggang Hu
Researcher at Beijing Jiaotong University
Publications - 26
Citations - 516
Honggang Hu is an academic researcher from Beijing Jiaotong University. The author has contributed to research in topics: Mesenchymal stem cell & Genome-wide association study. The author has an hindex of 11, co-authored 24 publications receiving 434 citations. Previous affiliations of Honggang Hu include University of Konstanz.
Papers
More filters
Journal ArticleDOI
The DEK protein—an abundant and ubiquitous constituent of mammalian chromatin
TL;DR: The available evidence strongly suggests that DEK could function as an architectural protein in chromatin comparable to the better known classic architectural chromatin proteins, the high-mobility group or HMG proteins.
Journal ArticleDOI
Inhibitory effect and mechanism of mesenchymal stem cells on liver cancer cells
Lingling Hou,Xiaoyu Wang,Yaqiong Zhou,Haibin Ma,Ziling Wang,Jin-Sheng He,Honggang Hu,Weijun Guan,Yuehui Ma,Yuehui Ma +9 more
TL;DR: A new approach and experimental basis for cancer therapy is provided and it is proved that the Wnt signaling pathway may have a function in MSC-mediated tumor cell inhibition.
Journal ArticleDOI
Suggestion of GLYAT gene underlying variation of bone size and body lean mass as revealed by a bivariate genome-wide association study
Yan-Fang Guo,Li-Shu Zhang,Yong-Jun Liu,Honggang Hu,Jian Li,Qing Tian,Ping Yu,Feng Zhang,Tie-Lin Yang,Yan Guo,Xiang-Lei Peng,Meng Dai,Wei Chen,Hong-Wen Deng,Hong-Wen Deng,Hong-Wen Deng +15 more
TL;DR: The importance of GLYAT gene in co-regulation of bone phenotypes and body lean mass is suggested, suggesting the gene’s dual role in both bone development and muscle growth.
Journal ArticleDOI
The distribution of the DEK protein in mammalian chromatin.
TL;DR: The conclusion is that DEK could serve as an architectural protein at the promoter or enhancer sites of a subfraction of human genes.
Journal ArticleDOI
Administration of amyloid-β42 oligomer-specific monoclonal antibody improved memory performance in SAMP8 mice.
Ying Zhang,Jin-Sheng He,Xin Wang,Jun Wang,Fu-Xiang Bao,Si-Yuan Pang,Fan Yin,Honggang Hu,Xiang-Lei Peng,Wei-Min Sun,Yan-Peng Zheng,Lingling Hou,Tao Hong,Tao Hong +13 more
TL;DR: The data suggest that a strain of monoclonal antibody A8 may be a candidate as a potential immunotherapeutic agent in AD, and shows that Aβ pathology was ameliorated with decreased Aβ oligomers and phospho-tau levels in SAMP8 mice.